Biogen Says Spinraza's Third Quarter Got A One-Time Lift, With Fourth-Quarter Growth Guided To A Mid-Single-Digit Rise
The drugmaker's finance chief tied a $461 million Spinraza quarter to one-time transition doses and pulled-forward conversions.
Biogen, the biopharmaceutical company behind the multiple sclerosis drugs Tysabri and Vumerity and the spinal muscular atrophy drug Spinraza, said on its third-quarter earnings call Wednesday that Spinraza revenue of $461 million got "a meaningful revenue tailwind" from one-time transition doses. Chief Financial Officer Robin Kramer guided fourth-quarter Spinraza revenue to up about a mid-single-digit percentage from the fourth quarter of 2025, and a Wells Fargo analyst asked why the outlook implies such a drop from the third quarter.
One-time boosts in the quarter
Kramer said the Spinraza tailwind came from patients converting from the low-dose regimen to high dose, which exceeded the company's expectations. Spinraza revenue rose 23% from a year earlier and 15% from the second quarter.
Two inventory builds also helped: about $12 million for Skyclarys and about $11 million for Syfovre, both expected to be drawn down in the fourth quarter. Syfovre's price will also return to historic levels after a one-time price benefit tied to a product launch, Kramer said. Even so, she guided Syfovre fourth-quarter revenue to up about a mid-single-digit percentage from the $155 million Apellis reported in the fourth quarter of 2025.
Total revenue was $2.8 billion, up 11% from a year earlier. Core pharmaceutical revenue was $2 billion, up 18%, and the growth portfolio brought in about $1.3 billion, up 49%.
"What are we missing?"
The Wells Fargo analyst said that applying roughly 5% growth and subtracting nine months of sales implied "quite a lot of drop sequentially" in the fourth quarter. The analyst asked, "What are we missing?"
Kramer answered that conversions expected in the fourth quarter were pulled into the third, along with the inventory effects. She said the raised low end of the 2026 earnings guidance, now $12.20 to $13 a share on an adjusted basis, was driven primarily by the Apellis integration, both its sales and faster cost synergies.
Alicia Alimo, President, North America, said 70% of eligible 12 mg patients had a start form submitted by the end of the third quarter and 50% had been dosed. Next year fewer patients will get the one-time transition-dose benefit, she said.
Apellis integration and cash
Biogen completed the Apellis purchase in May. Syfovre and Empaveli brought in $243 million in the quarter, and CEO Chris Viehbacher said the company is on track for at least $250 million of run-rate synergies by the end of 2027. Kramer said the deal is now roughly neutral at the operating level and less dilutive in 2026; she still expects it to add to adjusted earnings per share in 2027.
Biogen generated $600 million of free cash flow in the quarter and ended with $1.3 billion in cash and $6.4 billion of net debt. It repaid $400 million of acquisition term loans, $600 million in total, and expects to repay the remaining $1.4 billion by the end of 2027.
GAAP, or standard-accounting, earnings were a loss of 14 cents a share, weighed by $284 million of acquired research and milestone charges, higher amortization and restructuring costs.
Head of Development Priya Singhal said Biogen will disclose results from its two late-stage lupus studies of litifilimab in the first half of December.
Sources
- Biogen notches 3rd straight quarter of growth thanks to newer products, Apellis - BioSpace — biospace.com
- Biogen posts Q3 beat on multiple sclerosis drugs (BIIB:NASDAQ) | Seeking Alpha — seekingalpha.com
- Biogen Q3 Preview: Will Growth Products Drive an Earnings Beat? — Yahoo Finance
- Biogen Has 'Returned To Growth,' Says CEO — What To Know About Its Report — Yahoo Finance
- Biogen Crushes Earnings Estimates. As Old Blockbusters Fade, New Bets Pick Up the Slack. — Barron's